BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 32892697)

  • 21. Paeoniflorin inhibits human gastric carcinoma cell proliferation through up-regulation of microRNA-124 and suppression of PI3K/Akt and STAT3 signaling.
    Zheng YB; Xiao GC; Tong SL; Ding Y; Wang QS; Li SB; Hao ZN
    World J Gastroenterol; 2015 Jun; 21(23):7197-207. PubMed ID: 26109806
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MiR-124 changes the sensitivity of lung cancer cells to cisplatin through targeting STAT3.
    Qi MM; Ge F; Chen XJ; Tang C; Ma J
    Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5242-5250. PubMed ID: 31298375
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MicroRNA-200c regulates cisplatin resistance by targeting ZEB2 in human gastric cancer cells.
    Jiang T; Dong P; Li L; Ma X; Xu P; Zhu H; Wang Y; Yang B; Liu K; Liu J; Xue J; Lv R; Su P; Kong G; Chang Y; Zhao C; Wang L
    Oncol Rep; 2017 Jul; 38(1):151-158. PubMed ID: 28534959
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Ethoxysanguinarine directly targets CIP2A to inhibit proliferation and induce autophagy of SGC7901/DDP cells].
    Wan F; Tan M; Xiang YC; Liu XW; Peng P; Liu Y
    Zhongguo Zhong Yao Za Zhi; 2022 Nov; 47(21):5890-5899. PubMed ID: 36472008
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of CD133 Overcomes Cisplatin Resistance Through Inhibiting PI3K/AKT/mTOR Signaling Pathway and Autophagy in CD133-Positive Gastric Cancer Cells.
    Lu R; Zhao G; Yang Y; Jiang Z; Cai J; Hu H
    Technol Cancer Res Treat; 2019 Jan; 18():1533033819864311. PubMed ID: 31405336
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Silencing long non-coding RNA ROR improves sensitivity of non-small-cell lung cancer to cisplatin resistance by inhibiting PI3K/Akt/mTOR signaling pathway.
    Shi H; Pu J; Zhou XL; Ning YY; Bai C
    Tumour Biol; 2017 May; 39(5):1010428317697568. PubMed ID: 28459375
    [TBL] [Abstract][Full Text] [Related]  

  • 27. miR-106a confers cisplatin resistance by regulating PTEN/Akt pathway in gastric cancer cells.
    Fang Y; Shen H; Li H; Cao Y; Qin R; Long L; Zhu X; Xie C; Xu W
    Acta Biochim Biophys Sin (Shanghai); 2013 Nov; 45(11):963-72. PubMed ID: 24108762
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Exosomal microRNA-107 reverses chemotherapeutic drug resistance of gastric cancer cells through HMGA2/mTOR/P-gp pathway.
    Jiang L; Zhang Y; Guo L; Liu C; Wang P; Ren W
    BMC Cancer; 2021 Dec; 21(1):1290. PubMed ID: 34856955
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MiR-876-3p regulates cisplatin resistance and stem cell-like properties of gastric cancer cells by targeting TMED3.
    Peng C; Huang K; Liu G; Li Y; Yu C
    J Gastroenterol Hepatol; 2019 Oct; 34(10):1711-1719. PubMed ID: 30843262
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Co-treatment with BEZ235 enhances chemosensitivity of A549/DDP cells to cisplatin via inhibition of PI3K/Akt/mTOR signaling and downregulation of ERCC1 expression.
    Xia A; Li H; Li R; Lu L; Wu X
    Oncol Rep; 2018 Oct; 40(4):2353-2362. PubMed ID: 30066933
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MicroRNA-448 targets SATB1 to reverse the cisplatin resistance in lung cancer via mediating Wnt/β-catenin signalling pathway.
    Ning MY; Cheng ZL; Zhao J
    J Biochem; 2020 Jul; 168(1):41-51. PubMed ID: 32525527
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Deregulation of the miR-222-ABCG2 regulatory module in tongue squamous cell carcinoma contributes to chemoresistance and enhanced migratory/invasive potential.
    Zhao L; Ren Y; Tang H; Wang W; He Q; Sun J; Zhou X; Wang A
    Oncotarget; 2015 Dec; 6(42):44538-50. PubMed ID: 26517090
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-gastric cancer effect of Salidroside through elevating miR-99a expression.
    Yang L; Yu Y; Zhang Q; Li X; Zhang C; Mao T; Liu S; Tian Z
    Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):3500-3510. PubMed ID: 31432697
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Downregulated Long Non-Coding RNA MSC-AS1 Inhibits Osteosarcoma Progression and Increases Sensitivity to Cisplatin by Binding to MicroRNA-142.
    Zhang L; Zhao G; Ji S; Yuan Q; Zhou H
    Med Sci Monit; 2020 Mar; 26():e921594. PubMed ID: 32155139
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long Noncoding RNA Plasmacytoma Variant Translocation 1 Regulates Cisplatin Resistance via miR-3619-5p/TBL1XR1 Axis in Gastric Cancer.
    Wu C; Hu Y; Ning Y; Zhao A; Zhang G; Yan L
    Cancer Biother Radiopharm; 2020 Dec; 35(10):741-752. PubMed ID: 32407172
    [No Abstract]   [Full Text] [Related]  

  • 36. LncRNA KCNQ1OT1 contributes to the cisplatin resistance of tongue cancer through the KCNQ1OT1/miR-124-3p/TRIM14 axis.
    Qiao CY; Qiao TY; Jin H; Liu LL; Zheng MD; Wang ZL
    Eur Rev Med Pharmacol Sci; 2020 Jan; 24(1):200-212. PubMed ID: 31957833
    [TBL] [Abstract][Full Text] [Related]  

  • 37. XPC inhibition rescues cisplatin resistance via the Akt/mTOR signaling pathway in A549/DDP lung adenocarcinoma cells.
    Teng X; Fan XF; Li Q; Liu S; Wu DY; Wang SY; Shi Y; Dong M
    Oncol Rep; 2019 Mar; 41(3):1875-1882. PubMed ID: 30628719
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Toosendanin reduces cisplatin resistance in ovarian cancer through modulating the miR-195/ERK/β-catenin pathway.
    Wang G; Li L; Li Y; Zhang LH
    Phytomedicine; 2023 Jan; 109():154571. PubMed ID: 36610147
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MiR-374b-5p suppresses RECK expression and promotes gastric cancer cell invasion and metastasis.
    Xie J; Tan ZH; Tang X; Mo MS; Liu YP; Gan RL; Li Y; Zhang L; Li GQ
    World J Gastroenterol; 2014 Dec; 20(46):17439-47. PubMed ID: 25516656
    [TBL] [Abstract][Full Text] [Related]  

  • 40. miR-21 confers cisplatin resistance in gastric cancer cells by regulating PTEN.
    Yang SM; Huang C; Li XF; Yu MZ; He Y; Li J
    Toxicology; 2013 Apr; 306():162-8. PubMed ID: 23466500
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.